Oral GLP-1 Pill Matches Insulin's Heart Safety in High-Risk Type 2 Diabetes
ACHIEVE-4 confirms orforglipron's cardiovascular non-inferiority to insulin glargine with far less hypoglycemia in 2,749 patients.
Summary
Orforglipron is a once-daily oral pill that activates the GLP-1 receptor — the same target as semaglutide — but without requiring injection. The ACHIEVE-4 trial randomized 2,749 adults with type 2 diabetes and high cardiovascular risk to either orforglipron or injectable insulin glargine for a median of two years. Major adverse cardiovascular events (MACE-4) occurred in 4.2% of the orforglipron group versus 5.0% with insulin, confirming non-inferiority. Crucially, severe hypoglycemia was nearly three times less common with the pill, while gastrointestinal side effects were more frequent. With 62% fewer deaths numerically in the orforglipron arm — though deemed treatment-unrelated — the data position this first oral non-peptide GLP-1 agonist as a convenient, heart-safe alternative to insulin for metabolically at-risk patients.
Detailed Summary
Type 2 diabetes dramatically accelerates cardiovascular aging, and the choice of glucose-lowering therapy increasingly influences long-term cardiovascular and kidney outcomes. While injectable GLP-1 receptor agonists like semaglutide have shown cardiovascular benefit, no oral, non-peptide GLP-1 agent had established cardiovascular safety data — until now.
The ACHIEVE-4 trial enrolled 2,749 adults with type 2 diabetes, obesity or overweight, and established cardiovascular or chronic kidney disease across 317 sites in 16 countries. Participants were randomized 1:1 to once-daily oral orforglipron (up to 36 mg capsule) or titrated injectable insulin glargine and followed for a median of two years. The primary endpoint was time to first MACE-4 event: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for unstable angina.
Orforglipron met the pre-specified non-inferiority threshold. MACE-4 occurred in 4.2% of the orforglipron group versus 5.0% with insulin glargine (HR 0.84; 95% CI 0.59–1.20; p<0.0001 for non-inferiority). While not powered for superiority, the directional trend favored orforglipron. Clinically significant hypoglycemia — a major driver of cardiovascular events and aging-related falls — was nearly three times less common with orforglipron (6.8% vs. 19.2%). Gastrointestinal adverse events were substantially higher with the pill (62.1% vs. 14.2%), consistent with the GLP-1 class effect. Total deaths were 19 in the orforglipron group versus 43 in the insulin group, though the trial was not designed to adjudicate mortality differences.
For longevity-focused clinicians and patients, these findings are significant. A convenient oral agent with cardiovascular safety, reduced hypoglycemia risk, and likely metabolic and weight benefits represents a meaningful advance in managing one of the most aging-accelerating chronic conditions. The drug's sponsor, Eli Lilly, funded the study, and several authors hold industry ties, which warrants consideration. This summary is based on the abstract only.
Key Findings
- Orforglipron was non-inferior to insulin glargine for MACE-4 (HR 0.84; 95% CI 0.59–1.20) over 2 years.
- Severe hypoglycemia was nearly 3× less common with orforglipron (6.8%) than insulin glargine (19.2%).
- GI adverse events affected 62% of orforglipron users vs. 14% of insulin users — the main discontinuation driver.
- Numerically fewer deaths occurred with orforglipron (19 vs. 43), though most were deemed treatment-unrelated.
- Orforglipron is the first oral non-peptide GLP-1 agonist to establish cardiovascular safety data in a phase 3 trial.
Methodology
Phase 3, event-driven, randomized, open-label, active-comparator, non-inferiority trial across 317 sites in 16 countries. Adults with type 2 diabetes, BMI ≥25 kg/m², HbA1c 7.0–10.5%, and established cardiovascular or chronic kidney disease were randomized 1:1 to orforglipron or insulin glargine and followed for a median of 2 years. Non-inferiority was defined as an upper 95% CI hazard ratio below 1.8.
Study Limitations
The trial was designed for non-inferiority, not superiority, so cardiovascular benefit beyond insulin cannot be claimed. Industry funding by Eli Lilly and multiple author conflicts of interest warrant scrutiny. This summary is based on the abstract only; full methodology, secondary endpoints, and subgroup analyses are not available for review.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: